TABLE 9.
Significantly (p < 0.05; q < 0.1) elevated long-chain acylcarnitines and DAGs pre-exercise in the conditioned state (n = 8).
| Metabolite name | Pathway | Fold change (FC)* |
| Laurylcarnitine (C12) | Long-chain acylcarnitine | 2.16 |
| Myristoylcarnitine (C14) | Long-chain acylcarnitine | 1.93 |
| Palmitoylcarnitine (C16) | Long-chain acylcarnitine | 1.68 |
| Stearoylcarnitine (C18) | Long-chain acylcarnitine | 1.73 |
| Linoleoylcarnitine (C18:2) | Long-chain acylcarnitine | 1.75 |
| Arachidonoylcarnitine (C20:4) | Long-chain acylcarnitine | 1.99 |
| Adrenoylcarnitine (C22:4) | Long-chain acylcarnitine | 2.36 |
| Dihomo-linolenoylcarnitine (C20:3 n-3 or n-6) | Long-chain acylcarnitine | 1.86 |
| Diacylglycerol (16:1/18:2 [2], 16:0/18:3 [1]) | Diacylglyceride | 1.77 |
| Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] | Diacylglyceride | 1.55 |
| Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] | Diacylglyceride | 1.59 |
| Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] | Diacylglyceride | 1.87 |
| Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] | Diacylglyceride | 1.99 |
| Palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2] | Diacylglyceride | 1.34 |
| Palmitoyl-linoleoyl-glycerol (16:0/18:2) [1] | Diacylglyceride | 1.93 |
| Palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] | Diacylglyceride | 1.77 |
| Palmitoyl-linolenoyl-glycerol (16:0/18:3) [2] | Diacylglyceride | 1.61 |
| Stearoyl-linoleoyl-glycerol (18:0/18:2) [2] | Diacylglyceride | 1.52 |
*Fold change normalized to the pre-exercise time point in the unconditioned state.